Mission
AllTranz will be a leader in the development of innovative pharmaceutical products delivered via unique dermal solutions to treat a variety of neuroscience disorders. Potential new therapies include an array of neuroscience prodrugs as well as dermal delivery products. The AllTranz lead product is a proprietary synthetic cannabinoid for moderate to severe pain delivered via gel. The initial indication for the lead product is for the treatment of osteoarthritis. The company also plans to develop a second generation of this product that will be delivered via a proprietary transdermal patch, thereby extending patent life.